Neurocrine Biosciences is pleased to have received approval from the U.S Food and Drug Administration (FDA) for the new formulation on April 30 – more information can be found in our press release.
The new oral granules formulation provides an alternative administration option for those who have difficulty swallowing or prefer not to swallow whole capsules. We understand that people with HD have a unique set of needs and are pleased that this option will be available for those experiencing chorea.
Neurocrine is in the process of finalizing our launch plans, and we will keep you updated on when the new formulation will become available.
Please let us know if you receive any questions from the community that we can help to address, or you may contact Neurocrine Medical Information (877-641-3461; medinfo@neurocrine.com).